Provigil (Modafinil) and Simvastatin Interaction

Why This Interaction Matters Clinically

Modafinil (brand name Provigil) and simvastatin (brand name Zocor) are prescribed for entirely different conditions, yet they collide at the same metabolic bottleneck. Simvastatin is a prodrug that the liver converts to its active hydroxy acid form primarily through CYP3A4 [1]. Modafinil, per its FDA-approved labeling, is a moderate inducer of CYP3A4 at steady state [2].

The practical result: when a patient starts modafinil 200 mg daily while already taking simvastatin, hepatic CYP3A4 activity ramps up over 7 to 14 days. Simvastatin gets cleared faster, peak plasma concentrations drop, and the drug spends less time inhibiting HMG-CoA reductase. Robertson et al. demonstrated that chronic modafinil dosing reduced the AUC of the CYP3A4 probe substrate triazolam by approximately 59%, confirming clinically meaningful induction [3]. Simvastatin, classified by the FDA as a sensitive CYP3A4 substrate, would be expected to show a comparable reduction in exposure [4].

This is not a theoretical concern. The 2023 ACC/AHA guidelines emphasize that achieving target LDL-C reduction of ≥50% on high-intensity statin therapy is a cornerstone of ASCVD risk management [5]. A drug interaction that halves statin exposure can push a patient from therapeutic into sub-therapeutic territory without any visible symptom. The patient feels fine. The LDL creeps upward silently.

The CYP3A4 Mechanism in Detail

Modafinil upregulates CYP3A4 gene transcription through activation of the pregnane X receptor (PXR), a nuclear receptor in hepatocytes [6]. This is the same pathway used by rifampin, carbamazepine, and St. John's wort, though modafinil's induction potency is weaker than rifampin's.

CYP3A4 accounts for roughly 80% of simvastatin's first-pass metabolism in the gut wall and liver [1]. The enzyme converts simvastatin lactone to its active hydroxy acid form but also clears that active metabolite. When CYP3A4 activity increases, both the parent drug and the active metabolite are eliminated more rapidly. The net effect is lower systemic exposure to the pharmacologically active species.

A few numbers for context. Simvastatin's oral bioavailability is only about 5% under normal conditions because of extensive first-pass extraction [1]. Even a modest 30 to 50% increase in CYP3A4 activity can reduce that already-low bioavailability by a clinically significant margin. The Provigil prescribing information specifically warns that "blood levels of CYP3A4 substrates... may be reduced" and recommends dose adjustment when co-administered with drugs metabolized by this pathway [2].

The induction effect is not instantaneous. CYP3A4 protein synthesis takes several days to ramp up after modafinil initiation, with maximal induction typically reached by day 14 of continuous dosing [3]. This means the interaction may not manifest on a single-dose basis, which is why short-term co-administration (fewer than 5 days) carries less risk than chronic therapy.

Severity Rating and Clinical Classification

Most drug-interaction databases, including Lexicomp, Micromedex, and Clinical Pharmacology, classify the modafinil-simvastatin interaction as moderate severity, category C ("monitor therapy") [7]. This rating means the combination is not prohibited, but the prescriber should be aware of the interaction and adjust the treatment plan if warranted.

The FDA's own labeling stops short of calling the combination contraindicated. Compare this with the simvastatin-itraconazole pairing (strong CYP3A4 inhibitor), which is explicitly contraindicated because it raises simvastatin levels 10 to 20-fold and risks rhabdomyolysis [1]. The modafinil interaction moves in the opposite direction: it lowers simvastatin levels, so the safety risk is loss of efficacy rather than toxicity.

That distinction matters for clinical decision-making. A patient whose LDL-C is well controlled at 55 mg/dL on simvastatin 40 mg has a larger buffer. A patient hovering at 68 mg/dL on the same dose may lose control entirely if simvastatin exposure drops 40 to 50%.

Dose Adjustment Strategies

Three evidence-based approaches exist when modafinil and a statin must be co-prescribed. The right choice depends on the patient's cardiovascular risk profile and baseline LDL-C.

Option 1: Increase the simvastatin dose. If the patient is on simvastatin 20 mg, increasing to 40 mg can offset the reduction in drug exposure. The 2023 ACC/AHA guideline notes that doubling the statin dose produces an additional 6% LDL-C reduction on average [5]. This approach has a ceiling: simvastatin doses above 40 mg are restricted by the FDA due to myopathy risk, particularly the 80 mg dose, which carries a 0.9% incidence of myopathy compared with 0.02% at 20 mg [1].

Option 2: Switch to a non-CYP3A4 statin. Rosuvastatin (Crestor) is metabolized primarily by CYP2C9, with minimal CYP3A4 involvement [8]. Pitavastatin (Livalo) undergoes negligible CYP-mediated metabolism [9]. Neither statin's exposure is meaningfully altered by modafinil co-administration. For high-risk ASCVD patients, switching eliminates the interaction entirely. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced LDL-C by 50% and major cardiovascular events by 44% versus placebo [10].

Option 3: Monitor and hold. For patients on modafinil intermittently (shift-work disorder with rotating schedules), the CYP3A4 induction may not reach steady state. A fasting lipid panel 6 weeks after modafinil initiation can confirm whether LDL-C has risen meaningfully.

The American College of Clinical Pharmacy's 2020 drug-interaction management guideline states: "When a moderate CYP3A4 inducer is added to a regimen containing a sensitive CYP3A4 substrate, clinicians should reassess the substrate dose or consider therapeutic substitution within 2 to 4 weeks" [11].

Monitoring Protocol for Co-Prescribed Patients

A structured monitoring approach reduces the chance of silent LDL-C drift. The following timeline applies when modafinil is initiated in a patient already receiving simvastatin.

Baseline (day 0). Record the most recent fasting lipid panel and the current simvastatin dose. Document the modafinil dose and expected duration.

Week 4 to 6. Repeat fasting lipid panel. CYP3A4 induction should be at or near maximum by this point [3]. Compare LDL-C to baseline. An increase of ≥15% suggests clinically meaningful loss of statin efficacy.

Week 12. If a dose adjustment or statin switch was made at week 6, a follow-up lipid panel confirms the new regimen has restored LDL-C control. The 2018 AHA/ACC cholesterol guideline recommends checking a fasting lipid panel 4 to 12 weeks after any statin dose change [5].

Annually. Standard lipid monitoring per guideline recommendations. Flag any modafinil dose increase (e.g., from 200 mg to 400 mg) as a trigger for repeat assessment, since higher modafinil doses may produce greater CYP3A4 induction.

Liver transaminases do not need more frequent monitoring solely because of this interaction. The interaction reduces simvastatin exposure, so hepatotoxicity risk does not increase. The 2012 FDA safety communication removed the recommendation for routine liver enzyme monitoring in patients on statins [12].

Other Statins Affected by Modafinil

Simvastatin is the most vulnerable statin, but it is not the only one metabolized by CYP3A4. Lovastatin (Mevacor) is also a sensitive CYP3A4 substrate and would be expected to show a similar magnitude of interaction [1]. Atorvastatin (Lipitor) is a moderate CYP3A4 substrate; its exposure may decrease 30 to 40% with concurrent modafinil, though clinical data specific to this pair are limited [13].

The table below ranks statin susceptibility.

| Statin | CYP3A4 dependence | Expected interaction with modafinil | |---|---|---| | Simvastatin | High (sensitive substrate) | AUC decrease ~50% | | Lovastatin | High (sensitive substrate) | AUC decrease ~50% | | Atorvastatin | Moderate | AUC decrease ~30-40% | | Rosuvastatin | Minimal (CYP2C9) | No meaningful change | | Pitavastatin | Negligible | No meaningful change | | Pravastatin | None (not CYP-metabolized) | No meaningful change | | Fluvastatin | Minimal (CYP2C9) | No meaningful change |

For patients requiring both a wakefulness-promoting agent and lipid-lowering therapy, rosuvastatin or pitavastatin represents the cleanest pharmacokinetic choice.

Reverse Scenario: Stopping Modafinil While on Simvastatin

The interaction works in reverse when modafinil is discontinued. CYP3A4 activity returns to baseline over approximately 14 days as induced enzyme protein degrades [3]. Simvastatin exposure climbs back to its pre-modafinil level. If the simvastatin dose was increased to compensate for induction, the patient now faces a temporary period of higher-than-intended statin exposure.

The FDA label for simvastatin notes that the risk of myopathy is dose-related and that plasma concentrations of simvastatin acid correlate with muscle toxicity [1]. A patient whose simvastatin was titrated from 20 mg to 40 mg during modafinil therapy effectively returns to "40 mg without induction" status once modafinil stops. That exposure level is within the approved dose range and generally safe, but the prescriber should be aware of the pharmacokinetic shift.

The AHA Council on Clinical Pharmacology stated in a 2021 advisory: "Clinicians should anticipate rebound increases in substrate drug levels when an enzyme inducer is withdrawn and adjust dosing preemptively to avoid toxicity" [14].

Practical step: if modafinil is stopped, consider reducing simvastatin back to the pre-induction dose 2 weeks after the last modafinil dose, or simply recheck a lipid panel at 4 to 6 weeks and adjust based on results.

Modafinil's Other Clinically Relevant Interactions

The CYP3A4 induction that affects simvastatin also applies to other medications. The Provigil prescribing information highlights several categories [2].

Hormonal contraceptives. Modafinil reduces ethinyl estradiol exposure by approximately 18% at 200 mg/day and can compromise contraceptive efficacy [2]. The FDA label recommends alternative or additional contraception during modafinil use and for one month after discontinuation.

Cyclosporine. A case report documented a 50% reduction in cyclosporine blood levels after modafinil initiation in a renal transplant patient, requiring a dose increase to prevent rejection [15].

Midazolam and triazolam. Robertson et al. showed that modafinil 200 mg daily reduced triazolam AUC by 59% and Cmax by 42% after 28 days of co-administration [3]. This confirms the magnitude of CYP3A4 induction and serves as the pharmacokinetic anchor for predicting effects on other substrates.

Modafinil also inhibits CYP2C19 at therapeutic doses, which can raise levels of omeprazole, diazepam, and phenytoin [2]. This dual role as both inducer (CYP3A4) and inhibitor (CYP2C19) makes modafinil's interaction profile unusually complex for a drug often perceived as "mild."

Patient Counseling Points

Patients prescribed both medications should understand three things. First, the interaction does not cause a dangerous reaction; it makes the statin work less effectively. There is no acute symptom to watch for. Second, any new muscle pain, tenderness, or dark urine while on simvastatin warrants immediate medical contact regardless of modafinil use, as these are signs of rhabdomyolysis. The PRIMO study (N=7,924) found that 10.5% of patients on high-dose statin therapy reported muscular symptoms [16]. Third, patients should not adjust either medication on their own. Dose changes require a prescriber's assessment and a follow-up lipid panel.

Patients using simvastatin should take it in the evening, as the short half-life (2 to 3 hours for the active metabolite) means evening dosing aligns drug exposure with the liver's peak cholesterol synthesis period overnight [1]. Modafinil is typically taken in the morning, so there is no timing conflict between the two medications. Separating doses does not, however, prevent the interaction, because CYP3A4 induction is a systemic, 24-hour phenomenon.

Grapefruit juice is a CYP3A4 inhibitor and should still be limited in patients on simvastatin per the FDA label (no more than one quart daily) [1]. While the CYP3A4 induction from modafinil might partially offset the inhibition from grapefruit, the net effect is unpredictable, and avoidance remains the safest guidance.

Patients whose LDL-C was last measured more than 6 months ago should request a recheck within 4 to 6 weeks of starting modafinil at any dose of 200 mg or above.